Role of OATP transporters in the disposition of drugs

Pharmacogenomics

Volumn 8, Issue 7, 2007, Pages 787-802

  Niemi, Mikko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

OATP; OATP1B1; Organic anion transporting polypeptide; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics; SLCO; SLCO1B1; SNP

Indexed keywords

ATORVASTATIN; ATRASENTAN; AURANTIIN; BOSENTAN; CASPOFUNGIN; CELIPROLOL; DIGOXIN; ENALAPRIL; FEXOFENADINE; FLUINDOSTATIN; HESPERIDIN; IRINOTECAN; LEVOFLOXACIN; METHOTREXATE; OLMESARTAN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; PACLITAXEL; PITAVASTATIN; REPAGLINIDE; ROCURONIUM; ROSUVASTATIN; SAQUINAVIR; TEMOCAPRIL; THYROXINE; UNINDEXED DRUG; VASOPRESSIN;

APPLE JUICE; AREA UNDER THE CURVE; DNA SEQUENCE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG RESPONSE; DRUG UPTAKE; ETHNIC DIFFERENCE; GRAPEFRUIT JUICE; HUMAN; INTESTINE; KIDNEY PARENCHYMA; LIVER; ORANGE JUICE; PHARMACOGENOMICS; REVIEW;

ABSORPTION; HUMANS; ORGANIC ANION TRANSPORTERS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS;

EID: 34548103493     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.7.787     Document Type: Review

References (121)

1. Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78, 260-277 (2005).
2. Shitara Y, Horie T, Sugiyama Y: Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27, 425-446 (2006).
3. Marzolini C, Tirona RG, Kim RB: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5, 273-282 (2004).
4. Hagenbuch B, Meier PJ: Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447, 653-665 (2004).
5. König J, Seithel A, Gradhand U, Fromm MF: Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372, 432-443 (2006).
6. Smith NF, Figg WD, Sparreboom A: Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol. 1, 429-445 (2005).
7. Kerb R: Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234, 4-33 (2006).
8. Meier-Abt F, Mokrab Y, Mizuguchi K: Organic anion transporting polypeptides of the OATP/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode. J. Membr. Biol. 208, 213-227 (2005).
9. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N: Human organic anion transporter 1B1 (OATP1B1/OATP-C) and 1B3 (OATP1B3/OATP-8) function as bidirectional carriers and do not mediate GSH-bile acid co-transport. Am. J. Physiol. Gastrointest. Liver Physiol. (2007) (Epub ahead of print).
10. Kullak-Ublick GA, Hagenbuch B, Stieger B et al.: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109, 1274-1282 (1995).
11. Steckelbroeck S, Nassen A, Ugele B et al.: Steroid sulfatase (STS) expression in the human temporal lobe: enzyme activity, mRNA expression and immunohistochemistry study. J. Neurochem. 89, 403-417 (2004).
12. Lee W, Glaeser H, Smith LH et al.: Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280, 9610-9617 (2005).
13. Glaeser H, Bailey DG, Dresser GK et al.: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362-370 (2007).
14. Meier Y, Eloranta JJ, Darimont J et al.: Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos. 35, 590-594 (2007).
15. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866-871 (1999).
16. Maeda T, Takahashi K, Ohtsu N et al.: Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharm. 4, 85-94 (2007).
17. Fujino H, Saito T, Ogawa S, Kojima J: Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J. Pharm. Pharmacol. 57, 1305-1311 (2005).
18. Ho RH, Tirona RG, Leake BF et al.: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
19. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ: Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J. Pharmacol. Exp. Ther. 298, 110-115 (2001).
20. Su Y, Zhang X, Sinko PJ: Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol. Pharm. 1, 49-56 (2004).
21. Fujiwara K, Adachi H, Nishio T et al.: Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 142, 2005-2012 (2001).
22. Dresser GK, Bailey DG, Leake BF et al.: Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71, 11-20 (2002).
23. Dresser GK, Kim RB, Bailey DG: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77, 170-177 (2005).
24. Bailey DG, Dresser GK, Leake BF, Kim RB: Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81, 495-502 (2007).
25. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ: Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther. 73, 192-198 (2003).
26. Lilja JJ, Juntti-Patinen L, Neuvonen PJ: Orange juice substantially reduces the bioavailability of the β-adrenergic-blocking agent celiprolol. Clin. Pharmacol. Ther. 75, 184-190 (2004).
27. Hsiang B, Zhu Y, Wang Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168 (1999).
28. Abe T, Kakyo M, Tokui T et al.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274, 17159-17163 (1999).
29. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 +C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005).
30. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304, 610-616 (2003).
31. Kopplow K, Letschert K, König J, Walter B, Keppler D: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 68, 1031-1038 (2005).
32. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311, 139-146 (2004).
33. Schneck DW, Birmingham BK, Zalikowski JA et al.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75, 455-463 (2004).
34. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006).
35. Katz DA, Carr R, Grimm DR et al.: Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin. Pharmacol. Ther. 79, 186-196 (2006).
36. Treiber A, Schneiter R, Delahaye S, Clozel M: Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther. 308, 1121-1129 (2004).
37. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J: Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther. 81, 414-419 (2007).
38. Tamai I, Nezu J, Uchino H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273, 251-260 (2000).
39. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36, 164-172 (2002).
40. Sandhu P, Lee W, Xu X et al.: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. 33, 676-682 (2005).
41. Liu L, Cui Y, Chung AY et al.: Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 318, 395-402 (2006).
42. Maeda K, Ieiri I, Yasuda K et al.: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79, 427-439 (2006).
43. Nakagomi-Hagihara R, Nakai D, Kawai K et al.: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab. Dispos. 34, 862-869 (2006).
44. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y: Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos. 34, 1247-1254 (2006).
45. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33, 434-439 (2005).
46. Nozawa T, Sugiura S, Nakajima M et al.: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab. Dispos. 32, 291-294 (2004).
47. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 59, 602-604 (2005).
48. Niemi M, Backman JT, Kajosaari LI et al.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77, 468-478 (2005).
49. Regazzi MB, Iacona I, Campana C et al.: Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 25, 2732-2734 (1993).
50. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M: Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin. Pharmacol. Ther. 75, 101-109 (2004).
51. Simonson SG, Raza A, Martin PD et al.: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76, 167-177 (2004).
52. Hasunuma T, Nakamura M, Yachi T et al.: The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J. Clin. Ther. Med. 19, 381-389 (2003).
53. Lemahieu WP, Hermann M, Asberg A et al.: Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am. J. Transplant. 5, 2236-2243 (2005).
54. Arnadottir M, Eriksson LO, Thysell H, Karkas JD: Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 65, 410-413 (1993).
55. Ichimaru N, Takahara S, Kokado Y et al.: Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158, 417-423 (2001).
56. Park JW, Siekmeier R, Lattke P et al.: Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J. Cardiovasc. Pharmacol. Ther. 6, 351-361 (2001).
57. Mück W, Mai I, Fritsche L et al.: Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. 65, 251-261 (1999).
58. Olbricht C, Wanner C, Eisenhauer T et al.: Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62, 311-321 (1997).
59. Åsberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H: Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am. J. Transplant. 1, 382-386 (2001).
60. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT: Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 78, 388-399 (2005).
61. Tamai I, Safa AR: Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 265, 16509-16513 (1990).
62. Chen ZS, Kawabe T, Ono M et al.: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56, 1219-1228 (1999).
63. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565-581 (2006).
64. Binet I, Wallnofer A, Weber C, Jones R, Thiel G: Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 57, 224-231 (2000).
65. Fox RI, Morgan SL, Smith HT, Robbins BA, Choc MG, Baggott JE: Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford) 42, 989-994 (2003).
66. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685-691 (2002).
67. Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68, 122-129 (2000).
68. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69, 340-345 (2001).
69. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347-351 (2003).
70. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ: Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 30, 1352-1356 (2002).
71. Ogilvie BW, Zhang D, Li W et al.: Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 34, 191-197 (2006).
72. Shitara Y, Hirano M, Sato H, Sugiyama Y: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/ OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004).
73. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT: Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819-850 (2003).
74. Lau YY, Huang Y, Frassetto L, Benet LZ: Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81, 194-204 (2007).
75. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ: Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin. Pharmacol. Ther. 78, 154-167 (2005).
76. Jigorel E, Le Vee M, Boursier-Neyret C, Paramentier Y, Fardel O: Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 34, 1756-1763 (2006).
77. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 57, 181-187 (2004).
78. Campbell SD, de Morais SM, Xu JJ: Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem. Biol. Interact. 150, 179-187 (2004).
79. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229-1236 (2006).
80. Seithel A, Eberl S, Singer K et al.: The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35(5), 779-786 (2007).
81. Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
82. Niemi M, Schaeffeler E, Lang T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14, 429-440 (2004).
83. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223-228 (2003).
84. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y: Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14, 749-757 (2004).
85. Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003).
86. Nozawa T, Nakajima M, Tamai I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813 (2002).
87. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M: Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415 (2006).
88. Chung JY, Cho JY, Yu KS et al.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78, 342-350 (2005).
89. Lee E, Ryan S, Birmingham B et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005).
90. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. (2007) (Epub ahead of print).
91. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356-366 (2006).
92. Niemi M, Neuvonen PJ, Hofmann U et al.: Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics 15, 303-309 (2005).
93. Tachibana-Iimori R, Tabara Y, Kusuhara H et al.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375-380 (2004).
94. Igel M, Arnold KA, Niemi M et al.: Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther. 79, 419-426 (2006).
95. Morimoto K, Ueda S, Seki N et al.: OATP-C (OATP1B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients [abstract]. Clin. Pharmacol. Ther. 77, P21 (2005).
96. Niemi M, Kivistö KT, Diczfalusy U et al.: Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet. Genomics 16, 565-568 (2006).
97. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004).
98. Michalski C, Cui Y, Nies AT et al.: A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277, 43058-43063 (2002).
99. König J, Cui Y, Nies AT, Keppler D: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G156-G164 (2000).
100. Kullak-Ublick GA, Ismair MG, Stieger B et al.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525-533 (2001).
101. Smith NF, Marsh S, Scott-Horton TJ et al.: Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther. 81, 76-82 (2007).
102. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 4, 1030-1032 (2005).
103. Letschert K, Keppler D, Konig J: Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14, 441-452 (2004).
104. Schwarz UI, Dixit SG, Leake BF, Kim RB: Identification and functional characterization of OATP1B3 allelic variants using transfected HeLa cells [abstract]. Drug Metab. Rev. 38, 237 (2006).
105. Grube M, Kock K, Oswald S et al.: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80, 607-620 (2006).
106. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306, 703-708 (2003).
107. Schiffer R, Neis M, Holler D et al.: Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J. Invest. Dermatol. 120, 285-291 (2003).
108. Satoh H, Yamashita F, Tsujimoto M et al.: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 33, 518-523 (2005).
109. Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ: Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br. J. Clin. Pharmacol. 63(6), 732-740 (2007).
110. Ho RH, Leake BF, Kim RB, Wang Y: OATP2B1 allelic variants differentially transport rosuvastatin in vitro [abstract]. Drug Metab. Rev. 38, 240-241 (2006).
111. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol. Endocrinol. 16, 2283-2296 (2002).
112. Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J. Clin. Invest. 98, 1142-1149 (1996).
113. Adachi H, Suzuki T, Abe M et al.: Molecular characterization of human and rat organic anion transporter OATP-D. Am. J. Physiol. Renal Physiol. 285, F1188-F1197 (2003).
114. Huber RD, Gao B, Sidler Pfandler MA et al.: Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am. J. Physiol. Renal Physiol. 292, C795-C806 (2007).
115. Mikkaichi T, Suzuki T, Onogawa T et al.: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc. Natl Acad. Sci. USA 101, 3569-3574 (2004).
116. Chu X, Bleasby K, Yabut J et al.: Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human renal transporters hOAT3, OATP4C1, and MDR1 P-glycoprotein. J. Pharmacol. Exp. Ther. 321(2), 673-683 (2007).
117. Lee SY, Williamson B, Caballero OL et al.: Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immun. 4, 13 (2004).
118. Shimizu M, Fuse K, Okudaira K et al.: Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33, 1477-1481 (2005).
119. Abe T, Unno M, Onogawa T et al.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120, 1689-1699 (2001).
120. Ishiguro N, Maeda K, Kishimoto W et al.: Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos. 34, 1109-1115 (2006).
121. Nozawa T, Imai K, Nezu J, Tsuji AI: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308, 438-445 (2004).